Prellis Biologics: Antibody Discovery with AI & Immune DiversityPrellis Biologics: Antibody Discovery with AI & Immune DiversityPrellis Biologics: Antibody Discovery with AI & Immune DiversityContacts
linked inX - twitter

Harnessing the vast diversity of the human immune system

Integrating human biology with machine learning

We aim to revolutionize drug discovery by harnessing the power of the human immune system with tightly-integrated machine learning to develop next-generation antibody therapeutics with unparalleled speed, precision, and safety. We are committed to empowering our pharmaceutical partners with access to the most promising fully human antibody candidates, rapidly identified from the full human immune repertoire, enabling them to bring life-changing treatments to patients faster than ever before.

Our Team

Who We Are

Pioneering Discovery 

Pioneering Discovery 

Our EXIS™ platform revolutionizes antibody discovery, integrating natural immune processes and advanced AI to navigate the complexity of the human immune repertoire with unmatched precision and speed.

AI Integration

AI Integration

Artificial intelligence is at the core of our operations, enhancing the identification and optimization of antibodies, streamlining the path from lab to clinic.

Human Immune Replication

Human Immune Replication

By mirroring the human immune response in vitro, we access a vast diversity of antibodies, leveraging the natural repertoire with the benefit of an intrinsically low immunogenic risk profile, for therapeutic innovation.

Bioprinted Organoids

Bioprinted Organoids

Our advanced two-photon laser bioprinters create organoids with the proper 3D structure to recapture the complex biology of immune responses in vitro.

Diverse Antibody Library

Diverse Antibody Library

We tap into the genetic diversity of multiple donors, creating an extensive library of fully human antibodies, each with the potential to become a life-saving therapy.

Innovative Partnerships

Innovative Partnerships

Strategic collaborations amplify our impact, pairing our technological strengths with leading biotech and pharmaceutical partners to accelerate therapeutic development.

Our Investors

Celesta Capital (WRVI)Khosla VenturesAvidity PartnersSOSVBlack DiamondFuture VenturesTrue Ventures

Prellis engages in the strategic collaborations to advance next-generation antibody therapies

Partner With Us